New fused pyrroles with rA1/A2A antagonistic activity as potential therapeutics for neurodegenerative disorders.

Nadia Janse van Vuuren, Helena D Janse van Rensburg, Gisella Terre'Blanche, Lesetja J Legoabe

Abstract read

In one paragraph

Article in Molecular diversity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Functionalized 2,3'-Bipyrroles and Pyrrolo[1,2-Molecules (Basel, Switzerland) · 2024
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nadia Janse van VuurenCentre of Excellence for Pharmaceutical Sciences, North-West University, Private Bag X6001, Potchefstroom, 2520, South Africa.ORCID http://orcid.org/0000-0003-0710-3953

Helena D Janse van RensburgCentre of Excellence for Pharmaceutical Sciences, North-West University, Private Bag X6001, Potchefstroom, 2520, South Africa.ORCID http://orcid.org/0000-0001-5181-9428

Gisella Terre'BlancheCentre of Excellence for Pharmaceutical Sciences, North-West University, Private Bag X6001, Potchefstroom, 2520, South Africa.ORCID http://orcid.org/0000-0001-5586-3071

Lesetja J LegoabeCentre of Excellence for Pharmaceutical Sciences, North-West University, Private Bag X6001, Potchefstroom, 2520, South Africa. Lesetja.Legoabe@nwu.ac.za.ORCID http://orcid.org/0000-0003-2440-4993

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a pilot study, eleven pyrrolopyridine and pyrrolopyrimidine derivatives (specifically, 7-azaindole and 7-deazapurine derivatives) were synthesised by Suzuki cross-coupling reactions and evaluated via radioligand binding assays as potential adenosine receptor (AR) antagonists in order to further investigate the structure-activity relationships of these compounds. 6-Chloro-4-phenyl-1H-pyrrolo[2,3-b]pyridine, with a 7-azaindole scaffold, was identified as a selective A

Indexed as

Neurodegenerative DiseasesReceptor, Adenosine A2AHumansMolecular StructurePilot ProjectsPyrrolesStructure-Activity RelationshipPyrrolesReceptor, Adenosine A2A7-Azaindole derivatives7-Deazapurine derivativesAdenosine A1 and/or A2A receptor antagonistsAlzheimer’s diseaseParkinson’s diseasePyrrolopyrimidine analoguesSuzuki cross-coupling reactions

Identifiers

PMID34741275

DOI10.1007/s11030-021-10327-y

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.